Ongoing Assessments & Recent Research.
Easy access to our work
Asthma
Nov 2021Beta Thalassemia
Jun 2022Chemotherapy-Induced Neutropenia
Apr 2022COVID-19
Apr 2022Diabetes: Type 2
Jan 2022Hypertrophic Cardiomyopathy
Oct 2021Featured News & Insights.
Learn about our latest work.
ICER Publishes First Annual Assessment of Barriers to Fair Access Within US Commercial Insurance Prescription Drug Coverage
Scope of assessment limited by gaps in availability of payer policies and inability to evaluate how policies are implemented, highlighting importance of improving transparency to assure fair access.
12/01/2021ICER to Assess Gene Therapy for Beta Thalassemia
Report will be subject of New England CEPAC meeting in June 2022; Draft Scoping Document open to public comment until December 16, 2021.
11/24/2021ICER Publishes Evidence Report on Tezepelumab for Severe Asthma
Tezepelumab reduces asthma exacerbations, but there is uncertainty about long-term safety as with all new biologic therapies; tezepelumab would achieve common thresholds for cost-effectiveness if priced between $9,000 – $12,100 per year.
11/04/2021The ICER Impact.
New York Medicaid pursued discounts, many of which were in line with ICER reports, which have saved the state over $300 million
Engaged with over 300 patient groups and patient reps
In a landmark international program, HTA agencies around the world can now access ICER’s customizable COVID-19 Cost-Effectiveness Model
Current
Policy Papers.
Easy access to our ongoing policy papers
Barriers to Fair Access
First-ever scorecard of several key appropriate access criteria reveals variation across largest payers but high concordance for clinical eligibility criteria, step therapy, and provider restrictions; lower concordance found for formulary tiering criteria.
Unsupported Price Increases
Out of 10 identified drugs that had substantial 2020 price increases net of rebates on top of already high current spending, seven were not supported by new clinical evidence; net price increases on these seven drugs cost Americans an additional $1.67 billion in annual drug spend, of which nearly $1.4 billion was due to a single drug alone: Humira.
Strengthening the FDA’s Accelerated Approval Pathway
This paper aims to create a clearer understanding of both the opportunities and challenges inherent in the FDA’s accelerated approval pathway (AAP), and to present an analysis of the potential risks and benefits of a range of reform options that policymakers may consider in efforts to strengthen the AAP moving forward.
Latest
Developments.
We’re hiring! Click here to see our full time job listings.
Learn more about how the patient perspective influences ICER’s work, and learn how you can be involved.
Listen to our podcast, “A Prescription for Fair Pricing“. Subscribe now on Apple, Google, or Spotify.